The ATTRACT study: screening for the early identification of axial psoriatic arthritis in a cohort of Italian psoriatic patients.

Autor: Gentiloni, Michele Maria Luchetti, Paci, Valentino, Cimaroli, Ilaria, Agostinelli, Alice, Giannoni, Melania, Campanati, Anna, Diotallevi, Federico, Carotti, Marina, Sessa, Francesco, Sordillo, Raffaella, Macchini, Cristina, Fiorini, Federico, Massaccesi, Leonardo, Ciferri, Monia, Gigli, Marco, Marconi, Valentina, Perini, Lucia, Marani, Andrea, Giovagnoni, Andrea, Polonara, Gabriele
Předmět:
Zdroj: Rheumatology; Aug2024, Vol. 63 Issue 8, p2152-2161, 10p
Abstrakt: Objective There is growing interest in the early identification of patients with axial PsA (axPsA). We aimed to evaluate whether a dermatology-based screening strategy could help to identify axPsA patients. Methods The dermatologist-centred screening (DCS) questionnaire was administrated by dermatologists to consecutive patients fulfilling the inclusion criteria [(i) age ≥18 years and (ii) clinical diagnosis of psoriasis made by a dermatologist] to identify patients eligible (affirmative answers 1–3c of the DCS) for rheumatological evaluation. Clinical, laboratory, genetic and imaging data were collected from all referred patients. Results Among the 365 patients screened, 265 fulfilled the inclusion criteria and 124/265 (46.8%) were eligible for rheumatological referral. Diagnosis of axPsA, with or without peripheral PsA (pPsA), was made in 36/124 (29.0%) patients; pPsA without axial involvement was found in 21/124 (16.9%) patients. Back pain at screening was recorded in 174 (66%) patients, with 158 (60%) reporting a back pain duration longer than 3 months and 140 (53%) reporting back pain onset before the age of 45 years. Active inflammatory and/or structural post-inflammatory changes in the sacroiliac joints and/or spine were observed in all axPsA patients. Patients with PsA showed a numerically longer duration of back pain and higher CRP levels in comparison with patients with psoriasis without PsA. Conclusion The DCS tool proved to be a valuable screening strategy for detecting and characterizing patients with axPsA in a real-life cohort of psoriasis patients in a dermatological setting and helped to identify a substantial number of patients affected by undiagnosed pPsA. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index